| Application no. and date | 11164996.8 (espacenet) (Federated) (European Patent Register), 20070320 | | Patent/reg. no. and date | DK/EP 2364732, 20160706 | | Publication date | 20110914 | | Priority no. and date | EP 06111523, 20060322, EP 06021815, 20061018 | | EP pub. no. and date |
EP 2364732 20110914 | | Effective date | | | Applicant/owner | F. Hoffmann-La Roche AG, Grenzacher Strasse 124
4070 Basel, CH | | Applicant ref. no. | P59829DK01 | | Inventor | Friess, Thomas,
St. Martin-Strasse 8a
86911, Diessen-Dettenhofen, DE,
Hasmann, Max,
Rudolf-Zenker-Strasse 10
81377, München, DE,
Scheuer, Werner, PrimelstraÃYe 3
82377, Penzberg, DE | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 39/395 (2006.01) , C07K 16/00 (2006.01) | | Title | Tumorterapi med et antistof til vaskulær endotelvækstfaktor og et antistof til human epitelvækstfaktorreceptor type 2 | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | Ophævet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
